Главная > Поддержка > Справочные материалы

Справочные материалы

Receptor-Interacting Protein 3/Calmodulin-Dependent Kinase II/Proline-Rich Tyrosine Kinase 2 Pathway is Involved in Programmed Cell Death in a Mouse Model of Brain Ischaemic Stroke

Wang B, Ma L, Liu L, et al. Receptor-Interacting Protein 3/Calmodulin-Dependent Kinase II/Proline-Rich Tyrosine Kinase 2 Pathway is Involved in Programmed Cell Death in a Mouse Model of Brain Ischaemic Stroke. Neuroscience. 2022;506:14-28. doi:10.1016/j.neuroscience.2022.09.009

Рекомендуемые продукты: GAPDH покуплено у abinScience 2022-12-01
Design and Structural Optimization of Orally Bioavailable SOS1 Inhibitors for the Treatment of KRAS-Driven Carcinoma

He, H., Zhang, Y., Xu, J., Liu, Y., Wang, Z., Li, Y.,... & Zhang, S. (2022). Design and Structural Optimization of Orally Bioavailable SOS1 Inhibitors for the Treatment of KRAS-Driven Carcinoma. Journal of Medicinal Chemistry, 65(23), 16001-16016.

Рекомендуемые продукты: Recombinant Human KRAS/K-Ras 2 (G12C) Protein покуплено у abinScience 2022-11-17
Design and Structural Optimization of Orally Bioavailable SOS1 Inhibitors for the Treatment of KRAS-Driven Carcinoma

He, H., Zhang, Y., Xu, J., Liu, Y., Wang, Z., Li, Y.,... & Zhang, S. (2022). Design and Structural Optimization of Orally Bioavailable SOS1 Inhibitors for the Treatment of KRAS-Driven Carcinoma. Journal of Medicinal Chemistry, 65(23), 16001-16016.

Рекомендуемые продукты: Recombinant Human KRAS/K-Ras 2 (G12C) Protein покуплено у abinScience 2022-11-17
Molecular mimicry of the receptor-binding domain of the SARS-CoV-2 spike protein: from the interaction of spike-specific antibodies with transferrin and lactoferrin to the antiviral effects of human recombinant lactoferrin

Sokolov, A. V., Isakova‑Sivak, I. N., Mezhenskaya, D. A., Kostevich, V. A., Gorbunov, N. P., Elizarova, A. Yu., Matyushenko, V. A., Berson, Yu. M., Grudinina, N. A., Kolmakov, N. N., Zabrodskaya, Y. A., Komlev, A. S., Semak, I. V., Budevich, A. I., Rudenko, L. G., Vasilyev, V. B. (2022). Molecular mimicry of the receptor-binding domain of the SARS‑CoV‑2 spike protein: from the interaction of spike‑specific antibodies with transferrin and lactoferrin to the antiviral effects of human recombinant lactoferrin. Biometals, 36(3), 437–462.

Рекомендуемые продукты: Recombinant SARS-CoV-2 S - Trimer покуплено у abinScience 2022-11-05
Molecular mimicry of the receptor-binding domain of the SARS-CoV-2 spike protein: from the interaction of spike-specific antibodies with transferrin and lactoferrin to the antiviral effects of human recombinant lactoferrin

Sokolov, A. V., Isakova‑Sivak, I. N., Mezhenskaya, D. A., Kostevich, V. A., Gorbunov, N. P., Elizarova, A. Yu., Matyushenko, V. A., Berson, Yu. M., Grudinina, N. A., Kolmakov, N. N., Zabrodskaya, Y. A., Komlev, A. S., Semak, I. V., Budevich, A. I., Rudenko, L. G., Vasilyev, V. B. (2022). Molecular mimicry of the receptor-binding domain of the SARS‑CoV‑2 spike protein: from the interaction of spike‑specific antibodies with transferrin and lactoferrin to the antiviral effects of human recombinant lactoferrin. Biometals, 36(3), 437–462.

Рекомендуемые продукты: Recombinant SARS-CoV-2 S - Trimer покуплено у abinScience 2022-11-05
SARS-CoV-2 evolves to reduce but not abolish neutralizing action

Zhang Y, Ndzouboukou JB, Lin X, et al. SARS-CoV-2 evolves to reduce but not abolish neutralizing action. J Med Virol. 2023;95(1):e28207. doi:10.1002/jmv.28207

Рекомендуемые продукты: Research Grade Bamlanivimab Research Grade Casirivimab Research Grade lmdevimab Research Grade Etesevimab покуплено у abinScience 2022-10-19
SARS-CoV-2 evolves to reduce but not abolish neutralizing action

Zhang Y, Ndzouboukou JB, Lin X, et al. SARS-CoV-2 evolves to reduce but not abolish neutralizing action. J Med Virol. 2023;95(1):e28207. doi:10.1002/jmv.28207

Рекомендуемые продукты: Research Grade Bamlanivimab Research Grade Casirivimab Research Grade lmdevimab Research Grade Etesevimab покуплено у abinScience 2022-10-19
Discovery of Orally Bioavailable SOS1 Inhibitors for Suppressing KRAS-Driven Carcinoma

He, H., Zhang, Y., Xu, J., Li, Y., Fang, H., Liu, Y., Zhang, S., … (2022). Discovery of orally bioavailable SOS1 inhibitors for suppressing KRAS‑driven carcinoma. Journal of Medicinal Chemistry, 65(19), 13158–13171.

Рекомендуемые продукты: Recombinant Human KRAS/K-Ras 2 (G12C) Protein N-GST покуплено у abinScience 2022-09-29
Discovery of Orally Bioavailable SOS1 Inhibitors for Suppressing KRAS-Driven Carcinoma

He, H., Zhang, Y., Xu, J., Li, Y., Fang, H., Liu, Y., Zhang, S., … (2022). Discovery of orally bioavailable SOS1 inhibitors for suppressing KRAS‑driven carcinoma. Journal of Medicinal Chemistry, 65(19), 13158–13171.

Рекомендуемые продукты: Recombinant Human KRAS/K-Ras 2 (G12C) Protein N-GST покуплено у abinScience 2022-09-29
M6 A Modifier-Mediated Methylation Characterized by Diverse Prognosis, Tumor Microenvironment, and Immunother

Liu, F., et al. (2022). M6A modifier‑mediated methylation characterized by diverse prognosis, tumor microenvironment, and immunotherapy response in hepatocellular carcinoma. [Journal unspecified].

Рекомендуемые продукты: GAPDH покуплено у abinScience 2022-08-16

Получить бесплатный расчет